Clevidipine is a short-acting intravenous calcium channel blocker used for rapid blood pressure control in hospitalized patients. As a third-generation dihydropyridine, it selectively acts on vascular smooth muscle with minimal cardiac depression. The drug is formulated as an oil-in-water emulsion due to its extreme lipid solubility. It is metabolized by blood and tissue esterases, resulting in an ultra-short half-life of approximately one minute, allowing for precise titration and rapid offset of effect. This makes clevidipine particularly valuable in perioperative settings and hypertensive emergencies where tight hemodynamic control is required. Its metabolism is independent of hepatic and renal function.

Ethacrynic Acid is a potent loop diuretic active pharmaceutical ingredient (API). It acts by inhibiting the Na?/K?/2Cl? cotransporter in the thick ascending limb of the loop of Henle, promoting the excretion of sodium, chloride, and water. Primarily used to treat edema associated with congestive heart failure, hepatic cirrhosis, and renal disease, it is particularly valuable when patients show resistance to other diuretics like furosemide. As an ?,?-unsaturated ketone derivative, its mechanism involves binding to cysteine residues. Its use requires careful monitoring of electrolyte balance and renal function due to the risk of profound diuresis and ototoxicity.

Frovatriptan succinate is a high-purity active pharmaceutical ingredient (API) used as the potent, selective active component in antimigraine medications. It functions as a serotonin (5-HT1B/1D) receptor agonist, specifically developed for the acute treatment of migraine headaches with or without aura. By constricting dilated cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides, it effectively alleviates migraine pain, nausea, and sensitivity to light/sound. The succinate salt form enhances the stability and bioavailability of the frovatriptan molecule. As a second-generation triptan, it is characterized by a longer half-life, which may contribute to a lower rate of headache recurrence, making it a critical component in specific formulated migraine therapies.

Chloramine T (sodium N-chlorotoluene-p-sulfonamide) is an organic chlorine-releasing agent used as an antiseptic, disinfectant, and biocide in pharmaceutical and veterinary applications. As an Active Pharmaceutical Ingredient (API), it serves as a potent, broad-spectrum antimicrobial effective against bacteria, fungi, viruses, and spores. Its mechanism involves the generation of hypochlorous acid, leading to microbial oxidation. In pharmaceuticals, it is primarily employed in topical antiseptic formulations and disinfectant solutions. Handling requires care as it is a strong oxidizer and can release toxic chlorine gas under certain conditions. Its utility lies in its sustained release of active chlorine, providing prolonged disinfectant action.

Biapenem is a carbapenem antibiotic active ingredient (API) characterized by a broad spectrum of potent bactericidal activity. It is effective against a wide range of Gram-positive and Gram-negative bacteria, including many multidrug-resistant strains such as�Pseudomonas aeruginosa�and ESBL-producing Enterobacteriaceae. Its chemical structure provides enhanced stability against renal dehydropeptidase-I (DHP-I), eliminating the need for co-administration with a DHP inhibitor. The API works by inhibiting bacterial cell wall synthesis, leading to cell death. Manufactured under strict cGMP conditions, it is the essential component formulated into sterile injectable powders for the treatment of severe infections like pneumonia, sepsis, and intra-abdominal infections.

Chlorpromazine Hydrochloride is a phenothiazine-derived antipsychotic active pharmaceutical ingredient (API). It acts primarily as a dopamine antagonist, exerting its therapeutic effects in the central nervous system. This API is the cornerstone for the manufacture of medications used to manage psychotic disorders such as schizophrenia, to control severe nausea and vomiting, and to provide preoperative sedation. Its introduction in the 1950s revolutionized psychiatry. As a drug substance, it appears as a white or creamy white crystalline powder, soluble in water. Handling requires strict pharmaceutical GMP controls to ensure purity, potency, and consistency in final dosage forms like tablets and injectables.

Caspofungin acetate is a semisynthetic lipopeptide antifungal agent, acting as a potent non-competitive inhibitor of ?-(1,3)-D-glucan synthase. This enzyme is critical for fungal cell wall synthesis. By blocking it, caspofungin disrupts cell wall integrity, leading to osmotic lysis and death of susceptible fungal cells. It is specifically indicated for the treatment of invasive aspergillosis in patients refractory to or intolerant of other therapies, and for candidemia and other�Candida�infections. As an echinocandin, it offers a distinct mechanism of action from azoles and polyenes, with a favorable safety profile characterized by minimal renal toxicity. The active pharmaceutical ingredient (API) is typically supplied as a lyophilized powder for sterile intravenous solution formulation.

Darifenacin hydrobromide is an antimuscarinic active pharmaceutical ingredient (API) used in the treatment of overactive bladder (OAB). It acts as a selective antagonist of the M3 muscarinic acetylcholine receptor, which mediates detrusor muscle contraction in the bladder. This specific blockade reduces involuntary bladder contractions, thereby alleviating key OAB symptoms such as urgency, frequency, and urge incontinence. Its receptor selectivity is designed to minimize side effects associated with non-selective anticholinergics. The hydrobromide salt form improves the compound's stability and solubility for formulation into extended-release tablets. As a potent API, it is the critical component in prescription medications like Enablex�.

Clofarabine (API) is a purine nucleoside antimetabolite and second-generation deoxyadenosine analogue. As an active pharmaceutical ingredient, it functions by inhibiting DNA synthesis through incorporation into DNA strands and by disrupting DNA repair via ribonucleotide reductase inhibition. This dual mechanism induces apoptosis in rapidly dividing cells. Primarily indicated for relapsed/refractory acute lymphoblastic leukemia (ALL) in pediatric patients (1-21 years), it is administered intravenously. The API is typically supplied as a sterile, lyophilized powder for solution, requiring strict cold chain storage and aseptic handling due to its cytotoxic nature. Its use is constrained by a significant risk profile, including severe myelosuppression and capillary leak syndrome.

Cariprazine is an atypical antipsychotic API acting as a partial agonist with high affinity for dopamine D? and D? receptors, with preferential binding to D?. It also exhibits partial agonism at serotonin 5-HT?A receptors and antagonism at 5-HT?B receptors. This unique receptor profile underpins its efficacy in treating schizophrenia, manic/mixed episodes of bipolar I disorder, and as an adjunct for major depressive disorder. Its active metabolites, desmethyl- and didesmethyl-cariprazine, contribute significantly to its long pharmacokinetic half-life (~2-4 weeks at steady state). The synthesis involves multi-step organic chemistry to produce the final hydrochloride salt, requiring strict control over polymorphic forms and impurity profiles.

Chlorambucil is a nitrogen mustard alkylating agent used primarily as an antineoplastic chemotherapy drug. It belongs to the class of bifunctional alkylating agents derived from mustard gas. As an API (Active Pharmaceutical Ingredient), it works by cross-linking DNA strands, thereby inhibiting DNA replication and RNA transcription, which leads to the death of rapidly dividing cells, particularly malignant lymphocytes. It is a cornerstone in the treatment of chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphomas. The API is typically formulated into oral tablets. Chlorambucil is a pale cream-colored crystalline powder with limited solubility, requiring careful handling due to its cytotoxic and carcinogenic properties.

Chloramphenicol is a broad-spectrum bacteriostatic antibiotic. Its primary mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Originally derived from�Streptomyces venezuelae, it is now produced synthetically. As an Active Pharmaceutical Ingredient (API), it is a white to greyish-white or yellowish-white crystalline powder with a bitter taste. It is highly soluble in alcohol but poorly soluble in water. Due to the risk of serious and potentially fatal adverse effects, most notably bone marrow suppression (including aplastic anemia) and "gray baby syndrome" in neonates, its systemic use is now highly restricted. It is reserved for severe, life-threatening infections where other antibiotics are ineffective or contraindicated, such as certain cases of typhoid fever, meningitis, and rickettsial diseases. Topical formulations (e.g., for eye and ear infections) are more commonly used, as the risk of systemic toxicity is significantly lower.

Carmustine is a cytotoxic alkylating agent belonging to the nitrosourea class, used as an active pharmaceutical ingredient (API) in antineoplastic formulations. Its primary mechanism involves cross-linking DNA strands, inhibiting replication and transcription, which leads to cell death. It is particularly effective against rapidly dividing cells. As a highly lipophilic molecule, carmustine readily crosses the blood-brain barrier, making it a critical component in the treatment of brain tumors, including glioblastoma multiforme. It is also used for Hodgkin's lymphoma and multiple myeloma. Due to its instability in aqueous solutions, it is typically supplied as a lyophilized powder for reconstitution immediately before intravenous administration.

Bortezomib is a potent, selective, and reversible proteasome inhibitor used as an active pharmaceutical ingredient (API) in injectable formulations. It disrupts the ubiquitin-proteasome pathway, leading to the accumulation of pro-apoptotic proteins and subsequent programmed cell death. This mechanism of action is particularly effective against rapidly dividing cells, making it a cornerstone in the treatment of multiple myeloma and mantle cell lymphoma. The API is a modified dipeptidyl boronic acid, typically supplied as a lyophilized powder or solid. Its synthesis and handling require strict control due to its potency and instability in aqueous solutions, ensuring the final drug product meets stringent quality and sterility standards.

Carbidopa is a peripheral aromatic L-amino acid decarboxylase inhibitor used primarily in the treatment of Parkinson's disease. As an active pharmaceutical ingredient (API), it is almost exclusively administered in combination with levodopa (e.g., in Sinemet�). By inhibiting the peripheral conversion of levodopa to dopamine, carbidopa allows a greater proportion of levodopa to cross the blood-brain barrier. This significantly enhances the efficacy of levodopa therapy while minimizing peripheral side effects like nausea and cardiovascular disturbances. The API is typically formulated into oral tablets. Its introduction revolutionized Parkinson's management, enabling lower, more effective doses of levodopa and improving patients' quality of life.

Calcitriol API is the active pharmaceutical ingredient form of vitamin D3 (1,25-dihydroxycholecalciferol), the biologically potent hormone that regulates calcium and phosphate homeostasis in the body. Synthesized for pharmaceutical use, it directly activates vitamin D receptors in target tissues�primarily the intestines, bones, and kidneys. It is critically used to manage hypocalcemia in patients with chronic kidney disease on dialysis, hypoparathyroidism, and renal osteodystrophy. As a high-potency compound, its manufacture requires strict control for purity and stability. The API is formulated into oral capsules, injectable solutions, and topical preparations, with dosing carefully titrated to avoid hypercalcemia, its principal safety concern.

Buclizine hydrochloride is a piperazine-derived antihistamine API (active pharmaceutical ingredient) primarily used for its potent antiemetic and antinauseant properties. It acts as a histamine H1 receptor antagonist, effectively inhibiting the vestibular system to prevent and treat motion sickness and vertigo. The compound is typically formulated into oral tablets. Chemically, it is 1-[(4-chlorophenyl)phenylmethyl]-4-[(1,1-dimethylethyl)methyl] piperazine dihydrochloride. Its synthesis involves the alkylation of a substituted piperazine. As an API, it is supplied as a white to off-white crystalline powder, requiring storage in a tightly closed container, protected from light and moisture to ensure stability.

Trifluoperazine hydrochloride is a phenothiazine derivative antipsychotic active pharmaceutical ingredient (API). As a high-potency typical antipsychotic, it primarily functions as a dopamine D? receptor antagonist in the brain. It is indicated for the management of schizophrenia and other psychotic disorders, and is also used for short-term treatment of severe anxiety and nausea. The hydrochloride salt form enhances the stability and water solubility of the base compound, facilitating its formulation into oral tablets and injectable solutions. Its use requires careful medical supervision due to the risk of extrapyramidal symptoms and other significant side effects associated with first-generation antipsychotics.

Benazepril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor used as an active pharmaceutical ingredient (API) in antihypertensive and heart failure medications. As a prodrug, it is metabolized�in vivo�to its active form, benazeprilat. This compound works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, leading to vasodilation, reduced blood pressure, and decreased cardiac workload. The hydrochloride salt form ensures adequate stability and solubility for formulation. Benazepril HCl API is typically manufactured to high purity standards for use in solid oral dosage forms like tablets, often in combination with diuretics such as hydrochlorothiazide.

Anidulafungin API is a semi-synthetic echinocandin antifungal active pharmaceutical ingredient (API). It is derived from a fermentation product of�Aspergillus nidulans. As a potent fungicide, it non-competitively inhibits the synthesis of 1,3-?-D-glucan, an essential component of fungal cell walls, leading to osmotic instability and cell death. It is specifically indicated for the treatment of serious invasive candidiasis, including candidemia. Anidulafungin exhibits potent activity against�Candida�and�Aspergillus�species, with a favorable safety profile and minimal drug interactions due to its unique degradation pathway independent of hepatic cytochrome P450 enzymes. It is administered exclusively via intravenous infusion.

Calcitonin is a polypeptide hormone API (Active Pharmaceutical Ingredient) consisting of 32 amino acids. It is primarily used therapeutically to treat conditions involving excessive bone resorption, such as Paget's disease, hypercalcemia, and postmenopausal osteoporosis. As a hypocalcemic agent, it works by directly inhibiting osteoclast activity, thereby reducing bone turnover and calcium release into the bloodstream. The API is typically derived from synthetic or recombinant sources, ensuring purity and consistency. It is formulated for administration via injection or nasal spray. Strict quality control during manufacturing is essential to maintain its peptide structure, biological potency, and stability for clinical efficacy.

Bromfenac Sodium is a potent non-steroidal anti-inflammatory drug (NSAID) API, chemically derived from phenylacetic acid. As the sodium salt of bromfenac, it functions primarily as a selective cyclooxygenase-2 (COX-2) inhibitor, effectively reducing the synthesis of inflammatory prostaglandins. Its key advantages include high ocular penetration and sustained activity, making it the active pharmaceutical ingredient exclusively formulated for topical ophthalmic solutions. It is indicated for the treatment of postoperative inflammation and the reduction of ocular pain following cataract surgery. The API's strong efficacy at low concentrations and favorable safety profile for topical use have established it as a standard of care in ophthalmic anti-inflammatory therapy.

Acamprosate calcium API is a synthetic drug substance used in the maintenance of abstinence from alcohol in patients with alcohol dependence who are concurrently participating in a comprehensive management program. As an active pharmaceutical ingredient (API), it is chemically identified as calcium bis(N-acetylhomotaurinate). Its precise mechanism of action is not fully elucidated but is believed to involve modulation of the glutamatergic system, restoring the balance between neuronal excitation and inhibition disrupted by chronic alcohol use. The API is typically formulated into delayed-release enteric-coated tablets. It exhibits poor oral bioavailability and is not metabolized by the liver, being excreted unchanged primarily via the kidneys.

Triclabendazole is a benzimidazole derivative anthelmintic API specifically effective against�Fasciola hepatica�and�Fasciola gigantica�(liver flukes). Its primary mode of action is the disruption of parasite microtubule synthesis, leading to impaired tegumental function and eventual death. A key feature is its unique activity against both immature and adult fluke stages. It is classified as a Class II/IV BCS drug with poor aqueous solubility and high lipophilicity. The API is typically formulated as oral suspensions or tablets. As a veterinary and human pharmaceutical, it is considered the drug of choice for fascioliasis, with resistance being an emerging concern in veterinary use.

Afatinib API (C??H??ClFN?O?) is an orally administered small-molecule tyrosine kinase inhibitor (TKI) used as an active pharmaceutical ingredient (API) in targeted cancer therapy. It functions as a potent, irreversible inhibitor of the epidermal growth factor receptor (EGFR) family, covalently binding to ErbB receptors (EGFR, HER2, ErbB4). This mechanism blocks key signaling pathways that drive tumor cell proliferation and survival. The API is primarily formulated into tablets for treating metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations and advanced squamous cell carcinoma. As a second-generation TKI, afatinib is characterized by its irreversible binding and broader ErbB receptor inhibition compared to first-generation agents like gefitinib.

Capecitabine is an orally administered chemotherapeutic prodrug, primarily used to treat metastatic colorectal and breast cancers. It is enzymatically converted in the body into 5-fluorouracil (5-FU), which inhibits thymidylate synthase, disrupting DNA synthesis and halting tumor cell proliferation. This targeted activation maximizes efficacy at the tumor site while minimizing systemic exposure. The Active Pharmaceutical Ingredient (API) is a white to off-white crystalline powder, sparingly soluble in water. Its oral bioavailability offers a convenient alternative to intravenous 5-FU regimens. Quality specifications for the capecitabine API are strictly governed by pharmacopoeial standards (e.g., USP, Ph. Eur.) to ensure purity, potency, and patient safety.

Camostat is a synthetic serine protease inhibitor used as an active pharmaceutical ingredient (API) in anti-viral and anti-inflammatory medications. It functions by blocking transmembrane protease serine 2 (TMPRSS2), an enzyme crucial for viral entry, particularly for certain coronaviruses like SARS-CoV-2. Clinically, its primary approved use is in Japan for treating pancreatitis and postoperative reflux esophagitis. As an API, Camostat mesylate is formulated into oral tablets. Its potential application in inhibiting viral fusion has spurred significant research interest, especially during the COVID-19 pandemic, for repurposing as a host-directed antiviral therapy. It is known for its high potency and selectivity.

Cefepime is a fourth-generation cephalosporin antibiotic, characterized by a broad spectrum of activity against both Gram-positive and Gram-negative bacteria. Its key structural feature, a positively charged quaternary nitrogen in the side chain at the C-3 position, allows for rapid penetration through the outer membrane of Gram-negative pathogens. This property grants it enhanced stability against many beta-lactamases, including extended-spectrum beta-lactamases (ESBLs). Cefepime is indicated for the treatment of moderate to severe infections, such as pneumonia, bacteremia, and febrile neutropenia. It is typically administered via intravenous or intramuscular injection due to poor oral bioavailability. As an active pharmaceutical ingredient (API), it is formulated into sterile powders for solution.

Acyclovir API is an antiviral active pharmaceutical ingredient (API) primarily used to treat infections caused by herpes viruses, including herpes simplex (HSV-1, HSV-2) and varicella-zoster virus (VZV). Mechanism:�It is a nucleoside analogue that selectively inhibits viral DNA replication. Inside infected cells, viral enzymes phosphorylate acyclovir to its active triphosphate form, which competitively inhibits viral DNA polymerase and incorporates into the growing DNA chain, causing premature chain termination. Properties:�It is a white to off-white crystalline powder with the molecular formula C?H??N?O?. It has poor solubility in water.Applications:�Formulated as tablets, capsules, suspensions, topical creams, and intravenous injections for treating genital herpes, cold sores, shingles, and chickenpox.

Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor active pharmaceutical ingredient (API). It is a prodrug that undergoes hepatic hydrolysis to its active diacid metabolite, trandolaprilat. This metabolite inhibits ACE, preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This action leads to vasodilation, reduced aldosterone secretion, and decreased peripheral resistance. Primarily used in the synthesis of finished dosage forms for treating hypertension and heart failure post-myocardial infarction, the API is a white or almost white crystalline powder. It is manufactured under strict Good Manufacturing Practice (GMP) conditions to ensure purity, potency, and consistency for pharmaceutical formulation.

Tirofiban is a non-peptide antiplatelet agent acting as a specific and reversible glycoprotein IIb/IIIa receptor antagonist. It inhibits the final common pathway of platelet aggregation by preventing fibrinogen binding, thereby preventing thrombus formation. As an active pharmaceutical ingredient (API), it is formulated as a sterile solution for intravenous infusion, primarily used in the management of acute coronary syndromes, including unstable angina and non-Q-wave myocardial infarction, often during percutaneous coronary interventions. Its rapid onset and short half-life allow for precise clinical control. The API is synthesized under strict cGMP conditions, ensuring high purity and consistency for its critical therapeutic role in acute cardiac care.

Apalutamide API is a nonsteroidal antiandrogen (NSAA) used as an active pharmaceutical ingredient (API) in the treatment of prostate cancer. It functions as a potent and selective antagonist of the androgen receptor (AR), directly binding to it to inhibit androgen-induced receptor translocation and DNA binding. This action blocks the growth-stimulating effects of androgens on prostate cancer cells. Specifically indicated for non-metastatic and metastatic castration-sensitive prostate cancer, Apalutamide API is formulated into oral tablets. Its development represents a significant advancement in endocrine therapy, offering improved outcomes by targeting the AR signaling pathway even in the context of low testosterone levels.

Vilazodone is a novel psychotropic active pharmaceutical ingredient (API) classified as a serotonin partial agonist-reuptake inhibitor (SPARI). It combines two distinct mechanisms in a single molecule: selective serotonin reuptake inhibition (SSRI) and partial agonism of the 5-HT1A serotonin receptor. This dual action is intended to enhance antidepressant and anxiolytic efficacy while potentially mitigating side effects like sexual dysfunction and activation sometimes seen with SSRIs. As the API in the branded product Viibryd�, vilazodone hydrochloride is indicated for the treatment of major depressive disorder (MDD) in adults. Its synthesis involves multi-step organic chemistry to produce the potent, selective final compound in a highly purified solid form suitable for tablet formulation.

Bosutinib Monohydrate API is the monohydrate form of the active pharmaceutical ingredient bosutinib, a kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). It acts by specifically inhibiting the Bcr-Abl tyrosine kinase, which is the primary pathological driver in CML. The monohydrate form is a common crystalline solid-state form chosen for its stability, bioavailability, and manufacturability. As a key starting material, the API is synthesized under stringent Good Manufacturing Practice (GMP) conditions, ensuring high purity, consistent chemical structure, and compliance with global pharmacopeial standards (e.g., USP, EP) for incorporation into final oral solid dosage formulations.

Sodium Phenylbutyrate API is a white to off-white crystalline powder, soluble in water. As the sodium salt of phenylbutyric acid, it functions primarily as a nitrogen-scavenging agent in the treatment of urea cycle disorders, aiding in the excretion of excess ammonia. It acts as a prodrug, being metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, excreted renally. This essential active pharmaceutical ingredient is manufactured under strict GMP conditions, ensuring high purity and low endotoxin levels for parenteral and oral formulations. Its primary therapeutic role is in managing hyperammonemia.

Thiothixene is a first-generation (typical) antipsychotic medication, belonging to the thioxanthene chemical class. Its primary mechanism of action involves potent antagonism of dopaminergic D1 and D2 receptors in the central nervous system. As an Active Pharmaceutical Ingredient (API), it is formulated into oral capsules for the treatment of schizophrenia and other psychotic disorders. It is indicated for managing symptoms such as hallucinations, delusions, and thought disturbances. While effective, its use is often limited due to a significant risk of extrapyramidal side effects (EPS) and tardive dyskinesia. It has minimal antiemetic properties and some sedative effects.

Trazodone hydrochloride is a synthetic antidepressant API classified as a serotonin antagonist and reuptake inhibitor (SARI). Primarily used to treat major depressive disorder, its unique mechanism involves antagonism of 5-HT2A receptors while moderately inhibiting serotonin reuptake, which also promotes sleep. The white, crystalline powder is sparingly soluble in water. As an API, it is formulated into oral tablets. Beyond depression, it is widely prescribed off-label for insomnia due to its sedative properties. Key quality attributes include high purity, specified polymorphic form, and low levels of impurities like the chlorinated by-product. Its synthesis involves multi-step organic reactions, typically starting with a chlorinated phenylpiperazine intermediate.

Tolvaptan is a selective, competitive vasopressin V2 receptor antagonist used as an active pharmaceutical ingredient (API). It works by blocking the action of antidiuretic hormone in the kidneys, promoting the excretion of free water (aquaresis) without significant loss of electrolytes. This mechanism makes it the first oral pharmacotherapy specifically indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD) to slow kidney cyst growth and decline in function. It is also used to manage clinically significant hypervolemic and euvolemic hyponatremia. The API is typically formulated into tablets and requires careful dose titration due to risks of liver injury and rapid serum sodium correction.

Thalidomide is a synthetic glutamic acid derivative initially developed as a sedative. Its notorious history stems from severe teratogenic effects, causing limb malformations when prescribed to pregnant women for morning sickness in the late 1950s/early 1960s. Remarkably, it was later rediscovered for its potent immunomodulatory and anti-angiogenic properties. As an Active Pharmaceutical Ingredient (API), it is now critically used under strict risk mitigation programs to treat erythema nodosum leprosum (ENL) and multiple myeloma. Its mechanism involves binding to cereblon, modulating the activity of the CRL4CRBN E3 ubiquitin ligase complex, leading to the targeted degradation of specific proteins. Its handling requires extreme caution due to its teratogenicity.

Theophylline is a methylxanthine alkaloid used as a bronchodilator to treat respiratory diseases such as asthma and COPD. It works by relaxing bronchial smooth muscle and reducing airway inflammation, primarily through inhibition of phosphodiesterase enzymes and antagonism of adenosine receptors. This API is typically administered orally in sustained-release formulations to maintain stable plasma levels. Its narrow therapeutic index necessitates careful therapeutic drug monitoring due to significant interpatient variability in metabolism and potential for adverse effects like nausea, tachycardia, and seizures. Theophylline remains a cornerstone therapy, particularly for nocturnal asthma and severe cases, despite the development of newer agents.